Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

40th Annual J.P. Morgan Heathcare Conference – Presentation

Events, News, Presentations

40th Annual J.P. Morgan Heathcare Conference – Presentation Webcast, Jan 13, 2022 at 11:15AM EST...

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company...

Virtual KOL Event: Discussion of STRO-002 Interim Dose Expansion Cohort Data – Presentation

Events, News, Presentations

Virtual KOL Event: Discussion of STRO-002 Interim Dose Expansion Cohort Data – Presentation Webcast, Jan 5, 2022 at 5:00pm EST...

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer – 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both...

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer – Dr. Naumann and Sutro management to discuss interim data on the STRO-002 Phase 1...

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021

Events, News, Presentations, Press Releases

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021 – Nonclinical data for STRO-002 and STRO-001 are shared in two oral presentations at the 63rd American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif,...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.